CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-16). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 363 · Search date 2026-07-16 · Methodology v0.6

Evening primrose seed extract,
does it really help with Attenuation of postprandial blood-glucose rise?

30-Second Summary
C
Evidence Grade C · 48 · Safety unknown
The specified extract has a single-meal postprandial signal, but no independent replication or long-term clinical outcomes
What the
research shows
A small single-dose crossover study of an ethanolic extract from defatted evening primrose seeds reported lower post-rice blood glucose and insulin excursions in 16 healthy participants and 18 participants with borderline or mild diabetes. The rating is C because published support is concentrated in one manufacturer-linked extract, a single-dose surrogate outcome, and lacks independent replication or long-term HbA1c and complication outcomes.
What the
ads claim
Marketing can claim that PGG blocks sugar, solves glucose spikes, or prevents diabetes. Published human evidence concerns a single-meal curve for a specific seed extract. PGG is a specification marker and is not the gamma-linolenic acid found in evening primrose seed oil.
*

Useful facts when choosing a product

  • Korean health-functional-food products are formulated to provide 4 to 8.4 mg PGG daily under the regulatory specification, while tablet mass and additional ingredients vary.
  • Evening primrose seed extract is a polyphenol-rich ethanolic extract of defatted seeds and is different from evening primrose oil or GLA products.
  • The published human trial used 200 mg of extract once, so matching only the marketed PGG amount does not prove full equivalence to the study product.
  • People using glucose-lowering medication should discuss possible additive glucose reduction with a clinician, and long-term and pregnancy or lactation safety data are limited.
Gap Measurement · Verdict 363 · C 48
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Aitani 2003 human study used a crossover design in 16 healthy participants and 18 participants with borderline or mild diabetes, administering 200 mg extract or placebo with 200 g cooked rice and reporting lower postprandial glucose and insulin. A mechanistic paper from the same research network reported in-vitro alpha-glucosidase inhibition and rat starch-load results, which are not human clinical outcomes. The current Korean notified specification describes ethanol extraction after defatting, at least 20 mg/g PGG, a daily PGG intake of 4 to 8.4 mg, and a postprandial-glucose function.

02

Why this is classified as C (48)

A small single-dose human crossover trial means the evidence is not unknown, but positive support is limited to one manufacturer-linked extract and postprandial glucose and insulin surrogates. Lack of independent repetition and long-term clinical outcomes yields C with 48 points.

Counterpoint. A short-term signal for attenuating postprandial glucose with the specified extract exists, so the claim is not entirely unsupported.

Rejudgment record. Reassessment (cross-check reflected) — A positive small single-dose postprandial surrogate trial of one manufacturer-linked extract; regulatory status was not treated as independent replication

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Aitani M et al. 2003 human studyRandomized single-dose crossover trial18Manufacturer investigators including Oryza Oil and Fat ChemicalPost-rice blood glucose and insulin curvesSelected reductions in postprandial glucose and insulin excursions with 200 mg extract.Key; single manufacturer
Aitani M et al. 2003 mechanism studyIn-vitro and rat starch-load preclinical studyInvestigators from Oryza Oil and Fat Chemical and OtsukaAlpha-glucosidase inhibition and rat blood glucoseEnzyme inhibition and rat postprandial-glucose signals from polyphenol fractions; not a human outcome.Mechanistic support
MFDS notified standard 2-15Regulatory ingredient specificationMinistry of Food and Drug Safety, Republic of KoreaPGG specification, daily intake, and functional wordingSpecifies at least 20 mg/g PGG, 4 to 8.4 mg daily, and a postprandial-glucose function.Specification; not proof of efficacy
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-16).

Aitani M, Nishimura A, Hamada K, Koba T, Konishi Y. The Effects of an Extract of Seeds of Evening Primrose on Postprandial Hyperglycemia on Human Subjects. Nippon Shokuhin Kagaku Kogaku Kaishi. 2003;50(10):451-456. DOI: 10.3136/nskkk.50.451.
checked
Aitani M, Kimura H, Abiru Y, Soyama H, Murakami H, Zhang HL, Sugishita T, Konishi Y. Effect of an Extract from Evening-Primrose Seeds on Postprandial Blood Glucose Level and Its Active Components. Nippon Shokuhin Kagaku Kogaku Kaishi. 2003;50(4):180-187. DOI: 10.3136/nskkk.50.180.
checked
Ministry of Food and Drug Safety, Republic of Korea. Standards and Specifications for Health Functional Foods, 2-15 Evening Primrose Seed Extract. Accessed 2026-07-16.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none

Cite this verdict

Evening primrose seed extract (PGG) x postprandial blood glucose Evidence Grade C card
[Chamgap] Evening primrose seed extract (PGG) x postprandial blood glucose — Evidence Grade C·48. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/evening-primrose-seed-extract-postprandial-glucose/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.